U.S., Feb. 24 -- ClinicalTrials.gov registry received information related to the study (NCT07427680) titled 'Study of TGM-312-SC01 in Healthy Participants and Adults With MASH' on Jan. 30.
Brief Summary: The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamic (PD) effects of single ascending doses of TGM-312-SC01 in healthy adults and multiple ascending doses in patients with metabolic dysfunction-associated steatohepatitis (MASH).
Study Start Date: Feb., 2026
Study Type: INTERVENTIONAL
Condition:
Healthy Participants
MASH - Metabolic Dysfunction-Associated Steatohepatitis
Intervention:
DRUG: TGM-312-SC01
TGM-312-SC01 is an investigational medicinal product administered by subcut...